Efgartigimod for Guillain–Barré syndrome: a retrospective analysis of efficacy and safety
Efgartigimod shows efficacy as both a rapid-onset first-line therapy and a rescue option for refractory GBS, with a favorable safety profile and potential immunomodulatory effects, supporting further prospective evaluation.
Authors
- Xiaodong Ye (ORCID: https://orcid.org/0000-0003-2143-1726)
- Peidong Liu (ORCID: https://orcid.org/0000-0002-3869-2167)
- Hongbo Liu
- Zhuajin Bi
- Min Chen
- Mengcao Lu
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Therapeutic Advances in Neurological Disorders
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/17562864261419026
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00